Organization
Kennedy Institute of Rheumatology
3 abstracts
Abstract
102-wk clinical and radiologic results from the attract trial: a 2 year, randomised, controlled, phase 3 trial of infliximab (remicade®) in pts with active ra despite mtxOrg: Centocor, Kennedy Institute of Rheumatology, ATTRACT Investigator, Hammersmith Hospital, Imperial College, London, United Kingdom, Rheumatic Diseases, University of Cape Town, Cape Town, South Africa,
Abstract
BASELINE JOINT DAMAGE IS A SIGNIFICANT PREDICTOR OF IMPROVEMENT IN PHYSICAL FUNCTION IN RA PATIENTS AFTER TREATMENTOrg: Centocor, Inc., Kennedy Institute of Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases,
Abstract
BETWEEN-GROUP DIFFERENCES IN ULTRASONOGRAPHIC MEASURES OF SYNOVITIS AND KINETICS OF RESPONSE TO ORAL STEROIDS IN ACTIVE RAOrg: Kennedy Institute of Rheumatology, Imperial College, Clinical Pharmacology and Discovery Medicine, Respiratory and Inflammation, GlaxoSmithKline R and D, Stevenage, NGI CEDD, GlaxoSmithKline R and D, Harlow, RA Biology, GlaxoSmithKline R and D, Stevenage, United Kingdom, Rheumatology CEED, GlaxoSmithKline,